Etravirine
Also called Intelence is a drug used for the treatment of HIV / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Etravirine?
Summarize this article for a 10 year old
Etravirine (ETR,[1] brand name Intelence, formerly known as TMC125) is a drug used for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine.[2] Etravirine is marketed by Janssen, a subsidiary of Johnson & Johnson. In January 2008, the Food and Drug Administration approved its use for patients with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008.[3] It was also approved for use in Canada on April 1, 2008.[4]
Clinical data | |
---|---|
Trade names | Intelence |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608016 |
License data |
|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 99.9% |
Metabolism | Hepatic (CYP3A4, CYP2C9 & CYP2C19-mediated) |
Elimination half-life | 41±20 hours |
Excretion | Faeces (93.7%), urine (1.2%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
NIAID ChemDB | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.207.546 |
Chemical and physical data | |
Formula | C20H15BrN6O |
Molar mass | 435.285 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Etravirine is licensed in the United States, Canada, Israel, Russia, Australia, New Zealand and the European Union,[5] and is under regulatory review in Switzerland.[6]